Is This Huge Market Slowing Down?

Major joint companies aren't seeing a major pickup in demand for hips or knees

Jul 10, 2014 at 2:00PM

Waiting for a recovery in the orthopedic market isn't exactly waiting for Godot, but it has been frustrating all the same. Between modest (but steady) price pressure, lower patient volumes, and more assertive hospital customers, major ortho companies like Zimmer (NYSE:ZMH), Stryker (NYSE:SYK), and Johnson & Johnson (NYSE:JNJ) have had their work cut out to generate better results from what has historically been one of the largest medical device markets, and a profitable one at that.

As the second quarter earnings cycle revs up, Biomet has started things off with its fiscal fourth quarter report. Although there's nothing in the report that should worry Zimmer investors (Zimmer is in the process of trying to get regulatory approvals for its acquisition of Biomet), there is likewise not a lot to really encourage investors hoping for a major return to growth in the quarter.

Major joints mostly steady as she goes
Biomet reports on an off-calendar basis, which compromises comparability, and there are often company-specific factors (new product launches or announced launches on the way, etc.) that can likewise impair comparisons. Nevertheless, Biomet offers a few general takeaways.

Biomet reported roughly 6% organic growth for the fiscal fourth quarter (ended May 31, 2014), with constant currency growth of 4.6% in knees and 3.2% in hips and U.S. growth in those categories of 2.2% and 0.4%, respectively.

That's a marked deceleration from 6% yoy growth in hips in the first quarter, though that result was anomalous for both Biomet and the industry. Stryker has been quite strong here of late, growing 4% to 5% above the industry in 2013 before a slowdown to "market+3%" in the first quarter. Johnson & Johnson had been outgrowing the global hip market before Q1, while Zimmer and Smith & Nephew (NYSE:SNN) had been lagging. Biomet's result is a little disappointing and may well be pointing to continued sluggishness.

On the knee side, Biomet has been the market leader in growth terms for more than a year and will likely remain so, though Zimmer has been picking up momentum. Stryker's performance has been relatively feeble, while Johnson & Johnson has been matching the market as Smith & Nephew has lagged.

Spine, extremities, and trauma more idiosyncratic
Biomet's position in spine, trauma, and extremities make its results less predictive or indicative for the industry than in major joints. The 5% growth in sports medicine, extremities and trauma wasn't bad, but it seems likely that smaller, more extremities-focused companies will outperform. On the spine side, the company's results were boosted by an acquisition but it does appear that the overall spine market is getting healthier – good news for NuVasive, most likely.

A second request isn't too surprising
Zimmer and Biomet reported that they had received a second request from the FTC regarding their proposed merger. Given the size of the combined companies and the complexities of the merger, such a request is not very surprising.

As a reminder, the combined companies will have significant (and market-leading) share in both knees and hips. Given the past precedents of Medtronic in spine and Johnson & Johnson in spine and trauma, there likely won't be much push-back in major joints (and if Stryker gains more share in partial knee with MAKO, that won't hurt the Biomet-Zimmer case). Areas like shoulder could be more problematic, though, as I've seen estimated of their combined share ranging from 35% to 50%-at the high end, regulators may well push for divestitures.

The bottom line
Major orthopedic companies like Zimmer, Johnson & Johnson, and Stryker seem more or less resigned to an "it is what it is" level of low-to-mid single-digit market growth, with companies periodically grabbing or losing momentum on the basis of product launches, recalls, and so on. The spine, trauma, and extremities markets offer more upside, and that likely motivated Stryker's recent decision to acquire Small Bone Innovations. Looking at the quarter to come, it doesn't seem that the market is changing all that quickly and companies will have to continue to innovate or diversify to augment the sluggish growth in major joint reconstruction.

Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted this emerging technology is threatening his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. Find out how you can cash in on this technology before the crowd catches on, by jumping onto one company that could get you the biggest piece of the action. Click here to access a FREE investor alert on the company we're calling the "brains behind" the technology.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers